文献速递肝病消化道肿瘤与早癌

开发用于预测接受抗病毒治疗的亚洲慢性乙型肝炎患者肝细胞癌风险的评分系统

Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
PubMed 文献 · J Hepatol · 2018-03-16

本研究分析台湾和香港医疗数据库数据,开发并验证CAMD评分(肝硬化、年龄、男性、糖尿病,0-19分)预测恩替卡韦或替诺福韦治疗的慢性乙型肝炎患者肝细胞癌风险。开发队列23,851例台湾患者中596例(2.50%)发生肝细胞癌,3年累积发生率3.56%(95%CI 3.26-3.86%)。验证队列19,321例香港患者中,前3年c指数0.74-0.75,第4、5年均为0.76。评分<8分和>13分分别识别低危和高危患者。

要点

  • CAMD评分由肝硬化、年龄、男性、糖尿病构成,范围0-19分。
  • 开发队列c指数第1、2、3年分别为0.83、0.82、0.82。
  • 验证队列c指数前3年0.74-0.75,第4、5年均为0.76。

核心结论

  • 易于计算的CAMD评分可预测接受口服抗病毒治疗的慢性乙型肝炎患者肝细胞癌风险,并可能为监测策略提供信息。

研究设计与样本

  • 本研究分析台湾和香港医疗数据库的全人群数据,识别持续接受恩替卡韦或替诺福韦治疗的慢性乙型肝炎患者。
  • 开发队列包括台湾23,851例患者,其中596例(2.50%)发生肝细胞癌,3年累积发生率3.56%(95%CI 3.26-3.86%)。
  • 采用多变量Cox比例风险模型确定肝硬化、年龄(肝硬化与年龄存在交互作用)、男性、糖尿病为风险决定因素,并加权开发CAMD评分(0-19分)。
  • 该评分在香港19,321例患者中进行外部验证。

主要发现

  • 开发队列中肝细胞癌c指数在治疗第1、2、3年分别为0.83(95%CI 0.81-0.84)、0.82(95%CI 0.81-0.84)、0.82(95%CI 0.80-0.83)。
  • 验证队列中c指数在前3年分别为0.74(95%CI 0.71-0.77)、0.75(95%CI 0.73-0.78)、0.75(95%CI 0.72-0.77),外推第4、5年分别为0.76(95%CI 0.74-0.78)和0.76(95%CI 0.74-0.77)。
  • 两个队列中肝细胞癌的预测概率与观察概率均经过校准。
  • 评分<8分和>13分分别识别出肝细胞癌风险显著较低和较高的患者。

关键数值与推荐

  • CAMD评分范围0-19分,由肝硬化、年龄、男性、糖尿病构成。
  • 评分<8分和>13分分别识别肝细胞癌风险显著较低和较高的患者。
  • 开发队列c指数第1年0.83(95%CI 0.81-0.84)、第2年0.82(95%CI 0.81-0.84)、第3年0.82(95%CI 0.80-0.83)。
  • 验证队列c指数前3年0.74-0.75,外推第4、5年均为0.76。

临床怎么用

  • CAMD评分仅需治疗基线时的简单信息(即肝硬化、年龄、男性、糖尿病)即可计算。
  • 该评分可预测接受口服抗病毒治疗的慢性乙型肝炎患者肝细胞癌风险,并可能为监测策略提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The risk of hepatocellular carcinoma (HCC) during antiviral therapy in patients with chronic hepatitis B (CHB) is inadequately predicted by the scores built from untreated patients. We aimed at developing and validating a risk score to predict HCC in patients with CHB on entecavir or tenofovir treatment. METHODS: This study analysed population-wide data from the healthcare databases in Taiwan and Hong Kong to identify patients with CHB continuously receiving entecavir or tenofovir. The development cohort included 23,851 patients from Taiwan; 596 (2.50%) of them developed HCC with a three-year cumulative incidence of 3.56% (95% CI 3.26-3.86%). The multivariable Cox proportional hazards model found that cirrhosis, age (cirrhosis and age interacted with each other), male sex, and diabetes mellitus were the risk determinants. These variables were weighted to develop the cirrhosis, age, male sex, and diabetes mellitus (CAMD) score ranging from 0 to 19 points. The score was externally validated in 19,321 patients from Hong Kong. RESULTS: The c indices for HCC in the development cohort were 0.83 (95% CI 0.81-0.84), 0.82 (95% CI 0.81-0.84), and 0.82 (95% CI 0.80-0.83) at the first, second, and third years of therapy, respectively. In the validation cohort, the c indices were 0.74 (95% CI 0.71-0.77), 0.75 (95% CI 0.73-0.78), and 0.75 (95% CI 0.72-0.77) during the first three years, and 0.76 (95% CI 0.74-0.78) and 0.76 (95% CI 0.74-0.77) in the extrapolated fourth and fifth years, respectively. The predicted and observed probabilities of HCC were calibrated in both cohorts. A score <8 and >13 points identified patients at distinctly low and high risks. CONCLUSIONS: The easily calculable CAMD score can predict HCC and may inform surveillance policy in patients with CHB during oral antiviral therapy. LAY SUMMARY: This study analyses population-wide data from the healthcare systems in Taiwan and Hong Kong to develop and validate a risk score that predicts hepatocellular carcinoma during oral antiviral therapy in patients with chronic hepatitis B. The easily calculable CAMD score requires only simple information (i.e. cirrhosis, age, male sex, and diabetes mellitus) at the baseline of treatment initiation. With a scoring range from 0 to 19 points, the CAMD score discriminates the risk of hepatocellular carcinoma with a concordance rate of around 75-80% during the first three years on therapy. The risk prediction can be extrapolated to five years on treatment with similar accuracy. Patients with a score <8 and >13 points were exposed to distinctly lower and higher risks, respectively.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Hsu YC, Yip TC, Ho HJ, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018. PMID: 29551708. doi:10.1016/j.jhep.2018.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。